- Home
- AMZN vs ABBV Comparison
AMZN vs ABBV Comparison
Compare AMZN & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMZN | ABBV |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8T | 451.5B |
| IPO Year | 1997 | 2012 |
Fundamental Metrics
Financial Performance| Metric | AMZN | ABBV |
|---|---|---|
| Price | $248.13 | $285.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 60 | 30 |
| Target Price | ★ $331.46 | $282.61 |
| AVG Volume (30 Days) | ★ 25.1M | 3.2M |
| Earning Date | 10-29-2026 | 10-30-2026 |
| Dividend Yield | N/A | ★ 2.43% |
| EPS Growth | ★ 29.66 | N/A |
| EPS | ★ 8.53 | 2.42 |
| Revenue | ★ $716,924,000,000.00 | $61,160,000,000.00 |
| Revenue This Year | $15.57 | $10.57 |
| Revenue Next Year | $14.57 | $8.79 |
| P/E Ratio | ★ $29.30 | $117.54 |
| Revenue Growth | ★ 12.38 | 8.57 |
| 52 Week Low | $196.00 | $190.75 |
| 52 Week High | $287.20 | $291.40 |
Technical Indicators
Market Signals| Indicator | AMZN | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 65.69 |
| Support Level | $245.71 | $204.45 |
| Resistance Level | $250.15 | $291.40 |
| Average True Range (ATR) | 6.24 | 6.96 |
| MACD | -0.42 | 0.73 |
| Stochastic Oscillator | 7.56 | 83.53 |
Price Performance
Historical ComparisonAbout AMZN Amazon.com Inc.
Amazon is the leading online retailer and marketplace for third party sellers. Retail related revenue represents approximately 74% of total, followed by Amazon Web Services (17%), and advertising services (9%). International segments constitute 22% of Amazon's total revenue, led by Germany, the United Kingdom, and Japan.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.